Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
Date:11/8/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2012 financial results and highlighted key clinical development activities of its two product candidates, custirsen and OGX-427.

Custirsen Clinical Development Highlights

  • The Company announced completion of patient enrollment in the primary registration Phase 3 SYNERGY study. The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC). Over 1000 men have now been enrolled.  The survival primary endpoint data are event-driven and results are expected by the end of 2013.
  • The Phase 3 AFFINITY study, evaluating a survival benefit for custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in approximately 630 men with CRPC, was initiated in the third quarter. This global study will be conducted at sites throughout North America, Europe and Australia.
  • The ENSPIRIT trial, an international, randomized Phase 3 study in approximately 1,100 patients with advanced or metastatic non-small cell lung cancer (NSCLC), was initiated in the third quarter. The trial will evaluate the potential survival benefit of combining custirsen with docetaxel as a second-line chemotherapy in patients who have progressed after initial chemotherapy treatment has failed.
  • OGX-427 Clinical Development Highlights

  • Preliminary data from an investigator-sponsored Phase 2 clinical trial of OGX-427 in chemotherapy-naive patients with metastatic CRPC were presented at the European Society for Medical Oncology Annual Meeting (ESMO) in September 2012. The updated study results showed a higher number of patients without disease progression at 12 weeks and grea
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    4. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    5. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    6. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    7. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    9. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
    11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... SHENZHEN, China , 22 juli 2014 ... van BGI, ,s wereld grootste organisatie op het gebied ... nieuwe service ten behoeve van hele menselijke genoomsequentie via ... Genomics. In 2013 acquireerde BGI Complete ... aanzien staat vanwege de in eigen beheer ontwikkelde sequentietechnologieën ...
    (Date:7/22/2014)... , July 22, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today announced that it ... the open of U.S. financial markets on July 25, ... will host a conference call at 11 a.m. EDT, July ...
    (Date:7/22/2014)... July 22, 2014 Holomic is ... the debut of its fluorescent immunoassay reader, the ... (AACC) meeting in Chicago, July 28-31, 2014. Available ... versions, the HRDR-300 is a highly sensitive, low-cost ... analyze fluorescent lateral flow immunoassays with high sensitivity ...
    (Date:7/22/2014)... Dr. Williams says, “Bush has joined ... that the greatest health care system in the world ... deadly while trying to serve the public. Unfortunately, Bush ... transform an enormous system that none of them can ... continuing series of Open Letters ( http://is.gd/wdU2CM ) provides ...
    Breaking Biology Technology:BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
    ... of Wisconsin-Madison , justified or otherwise, is that its ... It has world-class scientists and well-developed mechanisms for turning ... of that commercialization takes place within a half-hour drive ... check the figures for per capita wages, unemployment and ...
    ... the fourth in a series of articles on developing start-up companies ... Madison, Wis. - In my last column for Stage 3, ... In the meantime, I received a thoughtful response about the ... column, dated November 17, 2006, discussed naming the entity. ...
    ... David Wittwer as CEO of TDS Telecom , , Madison, ... era of leadership at TDS Telecom , as Dave Wittwer ... the company announced. , ,Wittwer, 45, will become president and CEO ... TDS Metrocom . , ,He will be taking ...
    Cached Biology Technology:Entrepreneurship grant will build strong foundation 2Entrepreneurship grant will build strong foundation 3Entrepreneurship grant will build strong foundation 4Early Stage, Step 4: Cautionary trademark tales 2Early Stage, Step 4: Cautionary trademark tales 3
    (Date:7/22/2014)... to dust mites (and chances are you are), help ... University of Iowa have developed a vaccine that can ... response. In animal tests, the nano-sized vaccine package lowered ... the allergens, according to the paper, published in the ... Journal . One big reason why it works, the ...
    (Date:7/22/2014)... Schaeffer Center for Health Policy and Economics have ... increased incarceration rates for schizophrenic individuals. , The ... in mental health actually save money, when other ... plans require an extra approval step before tests ... step called prior authorization is intended ...
    (Date:7/22/2014)... probiotic that prevents obesity could be on the ... the gut inhibit weight gain, insulin resistance and ... mice, Vanderbilt University investigators have discovered., "Of course ... said senior investigator Sean Davies, Ph.D., assistant professor ... the negative consequences of obesity in mice, even ...
    Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Are state Medicaid policies sentencing people with mental illnesses to prison? 2Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2
    ... or proliferation, of jellyfish have shown a substantial, visible ... stinging waters for tourists, even choked intake lines for ... a perception that the world,s oceans are experiencing increases ... warming and overharvesting of fish. Now, a new ...
    ... An international survey led by Simon Fraser University,s Gerontology ... Stockholm Environment Institute (SEI) is tracking attitudes about the ... involves a consortium of organizations, will provide a snapshot ... issues as climate change. The survey aims ...
    ... from severe pulmonary diseases including emphysema, lung cancer or ... best chance for survival. The surgical procedure, however, faces ... and rejection of transplanted tissue by the recipient,s immune ... Lung Center (Principal Investigator for this project) in collaboration ...
    Cached Biology News:Global experts question claims about jellyfish populations 2Survey tracks '55+' attitudes about the environment 2Lungs clothed in fresh cells offer new hope for transplant patients 2Lungs clothed in fresh cells offer new hope for transplant patients 3
    ...
    ... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
    ... the Adept CE 4100 high pressure dual piston ... wavelength detector for added flexibility. The ... and interface unit, CE 4901., The CE 4901 ... be used with Windows 98 and 2000, offers ...
    ... cell culture scale-up, these culture chambers produce ... 10 9 range and are useful ... flasks. • High mechanical • strength and ... to shipping • Certified nonpyrogenic and sterilized ...
    Biology Products: